At #JPM2026 , CSL ’s new Global Head of Search & Evaluation, Stephen Pitt, PhD, joined Endpoints News News to spotlight the company’s century‑long record of advancing treatments for rare and serious diseases. From pioneering gene therapies in haemophilia B to delivering first‑in‑class options for hereditary angioedema, Stephen shared how CSL scales impact by partnering with the best and brightest innovators. Beyond our 100+ partnering meetings around Union Square, San Francisco this week, we’re busy connecting with biotech leaders and entrepreneurs across hematology, cardiovascular/renal, and immunology to co‑develop the next generation of breakthrough medicines. If you’re advancing new therapies with the potential to change patient lives, CSL would welcome a conversation. We’re a $55 billion global biotech that invests $1.4 billion annually in R&D to deliver therapies and vaccines to people in over 100 countries. Let’s shape the next century of innovation together! #CSL
Applications for the 2026 CSL Research Acceleration Initiative (RAI) are now open
CSL's Research Acceleration Initiative supports early stage biotechs and research organizations to fast-track the discovery of groundbreaking biotherapies.
Like to learn more about Our Impact? Click here to view or download the 2025 Impact Report → | Would you like to read our 2025 Annual Report? Click here to view or download the Annual Report → | CSL's 2025 Full Year Financial Results Click here for Full Information including Webcast Recording →
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and Products
CSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL Behring
CSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL Seqirus
CSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL ViforVita: Original Stories
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.
Careers at CSL
We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?
Pictured: A CSL employee in Bern, Switzerland
What does life with chronic kidney disease really look like? It’s more than dialysis machines and doctor visits. It’s about resilience and holding onto dreams. Last fiscal year, CSL medicines treated 184,000 patients for conditions associated with #kidneydisease . Learn more about how CSL makes an impact on kidney care: www.csl.com/impact #CSL #CSLImpactReport #ChronicKidneyDisease
At CSL, we turn big ideas into reality. Protecting public health is in the DNA of who we are and our newest manufacturing site at Tullamarine, Melbourne reflects that mission back every day in a modern, efficient, and highly scalable way. Learn more about how this high-tech vaccine and antivenom manufacturing facility is helping meet needs in the Southern Hemisphere. https://bit.ly/4pNewdn #CSL #CSLSeqirus #Manufacturing #Tullamarine #Melbourne #Australia #Antivenom #Innovation
CSL is investing $1.5 billion to expand global plasma therapy capabilities, strengthening supply, accelerating innovation and meeting the growing needs of patients worldwide. It’s one of many ways our teams drive meaningful change in plasma science and manufacturing. Help shape the future of lifesaving therapies: https://bit.ly/4sCGn2C #CSLCareers #Innovation #Impact #LifeSciences #PlasmaScience #CSL
Join CSL's new VP and Head of Search & Evaluation Stephen Pitt, PhD, at Endpoints at #JPM26 this Monday. Attend live or virtually to hear how we’re partnering to fuel CSL's Second Century of Global Biotech Innovation. Find the full agenda and registration info here: https://bit.ly/49tYWgq
Women are disproportionately affected by anemia, yet many still face gaps in diagnosis, treatment and support. At CSL, we’re committed to advancing equity in rare and serious conditions, including efforts to close the gender gap in anemia care. Through partnerships like the Blood & Beyond alliance, which we joined in December 2024, we’re working with experts, advocates and health systems to improve awareness, access and outcomes for patients worldwide. See how your work can support meaningful change: https://bit.ly/4jvN1DI #CSLCareers #RareDisease #Advocacy #PatientFocus #CSL
🎇 Here’s to a bright new year ahead. Wishing everyone health, happiness, and new possibilities in 2026! ✨ #HappyNewYear #CSL
From all of us at CSL, warm holiday wishes to you and yours. Here’s to a joyful and uplifting season! 🎁✨ #CSL #HappyHolidays
Hemophilia B is sometimes called “Christmas disease,” but the name has nothing to do with the holiday. It comes from the first patient diagnosed in 1952, a 5-year-old boy named Stephen Christmas. This discovery changed the way #hemophilia was understood and paved the way for decades of progress in treatment and care. Read more about the history and what it means for patients today: https://bit.ly/4jktCpe #HemophiliaB #Science #CSL
At CSL, culture is built on connection, collaboration and care, because people are at the heart of everything we do. Meet Natalie and Trevor, who share how CSL’s supportive environment and meaningful work have helped them grow both personally and professionally. #CSLCareers #PromisingFutures #LifeAtCSL See what makes CSL a place where purpose and possibility thrive: https://bit.ly/3L3Kvri